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Abstract
Background: Since the 1990s, influenza A viruses of the H9N2 subtype have been causing infections in the poultry
population around the globe. This influenza subtype is widely circulating in poultry and human cases of AI H9N2
have been sporadically reported in countries where this virus is endemic in domestic birds. The wide circulation of
H9N2 viruses throughout Europe and Asia along with their ability to cause direct infection in mammals and
humans, raises public health concerns. H9N2 AI was reported for the first time in Iran in 1998 and at present it is
endemic in poultry. This study was carried out to evaluate the exposure to H9N2 AI viruses among poultry workers
from the Fars province.
Methods: 100 poultry workers and 100 healthy individuals with no professional exposure to poultry took part in
this study. Serum samples were tested for antibodies against two distinct H9N2 avian influenza viruses, which
showed different phylogenetic clustering and important molecular differences, such as at the amino acid (aa)
position 226 (Q/L) (H3 numbering), using haemagglutination inhibition (HI) and microneutralization (MN) assays.
Results: Results showed that 17 % of the poultry workers were positive for the A/chicken/Iran/10VIR/854-5/2008
virus in MN test and 12 % in HI test using the titer ≥40 as positive cut-off value. Only 2 % of the poultry workers
were positive for the A/chicken/Iran/12VIR/9630/1998 virus. Seroprevalence of non exposed individuals for both
H9N2 strains was below 3 % by both tests. Statistical analyses models showed that exposure to poultry significantly
increases the risk of infection with H9N2 virus.
Conclusions: The results have demonstrated that exposure to avian H9N2 viruses had occurred among poultry
workers in the Fars province of Iran. Continuous surveillance programmes should be implemented to monitor the
presence of avian influenza infections in humans and to evaluate their potential threat to poultry workers and
public health.
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Background
Most emerging diseases are of zoonotic origin, with wild
and domestic animals acting as natural reservoirs [1].
Globalization and intensive animal farming have led to an
increased spread of zoonotic infections [2]. Influenza type
A viruses include several distinct subtypes based on the
antigenic properties of the two major surface glycopro-
teins, the hemagglutinin (HA) and the neuraminidase
(NA). To date, 18 subtypes of HA (H1-H18) and 11 sub-
types of NA (N1-N11) have been described [3]. A number
of influenza A subtypes have successfully crossed the spe-
cies barrier and have established in the mammals and hu-
man population, causing yearly seasonal epidemics or they
have sporadically been directly transmitted from poultry
to humans causing zoonotic infections [4, 5]. The influ-
enza A viruses of the H9N2 subtype are classified as low
pathogenic avian influenza (LPAI) viruses. They cause in-
fections both in wild birds and in the poultry population
worldwide, including several countries in Asia, Europe,
North Africa and North America [6, 7]. A significant pro-
portion of recent H9N2 avian influenza (AI) isolates con-
tains the L226Q (H3 numbering) amino acid substitution
in their hemagglutinins (HAs) showing preferential bind-
ing to analogs of receptors with sialic acid linked to galact-
ose by α2,6 linkage (SAα2,6Gal), a phenotypic portrait
which is characteristic of human influenza viruses. Thus,
these AI viruses might possess one of the key elements for
infection in humans [8–10]. Indeed, H9N2 viruses were
isolated for the first time from humans in Hong Kong in
1999 and further human infections were reported in 2003
[11, 12]. These studies have shown that avian H9N2 vi-
ruses isolated from chickens are closely related to the
H9N2 viruses responsible for human infection [13]. One
human case of H9N2 AI was reported in Bangladesh [14]
and the World Health Organization (WHO) in 2015 has
reported new cases in Egypt and Bangladesh [15, 16]. In
1998, domestic pigs from Hong Kong were confirmed as
being infected with H9N2 influenza, and infections have
been reported also in recent years in swine along with
other mammals [17, 18]. Furthermore, H9N2 viruses can
contribute with gene segments during reassortment
events leading to the generation of novel avian influenza
virus that can infect humans (e.g. recent Chinese H7N9
and H10N8 viruses) [19, 20]. Recent transmission studies
have demonstrated that some natural isolates of H9N2 vi-
ruses can acquire the ability to transmit efficiently be-
tween ferrets via respiratory droplets. In addition, it has
been reported that serial passages of an H9N2 virus
through guinea pigs can result in the introduction of
amino acid substitutions, which increases contact trans-
mission efficiency in this mammalian model [21, 22].
The wide circulation of H9N2 viruses throughout
Eurasia, along with their ability to cause direct infections
in mammals and humans, raises public health concerns
on their potential role as candidates for the next influ-
enza pandemic [23]. H9N2 human infection is generally
asymptomatic or responsible for mild clinical signs. This
may explain the scarcity of evidence accounting for the
circulation and transmission of this virus subtype [24].
Nonetheless, human sera positive for H9 subtype were
identified in China, India, Iran, Thailand, Cambodia,
Romania, Egypt and Pakistan [25–34].
In Iran, the H9N2 subtype was identified for the first
time in 1998 and is still circulating in the poultry popula-
tion. In the affected farms the mortality rate ranges
between 20 and 60 %, although this may also be attribut-
able to co-infections with other pathogens, such as IBV or
Mycoplasma gallisepticum [35]. In spite of the imple-
mented national control measures, which include the mass
vaccination of poultry, the virus has rapidly spread and can
be considered endemic in the Iranian poultry [36].
Exposure to H9N2 AI viruses in Iranian poultry
workers was previously revealed by means of HI test,
using serum titre ≥20 as positive cut-off [28, 29]. In pre-
vious reported studies, the H9N2 AI seroprevalence,
assessed by means of HI test, in Iranian poultry workers
ranged from 1.6 to 15.7 % (Median 9.5). Amongst the
Middle-Eastern and Southern Asia countries, the highest
seroprevalence was observed in Pakistan (47.8 %) by
means of HI test [34] and 7.5 % by means of MN test in
Egypt [33]. In the present study, two different serological
tests were used and compared to screen 200 individuals
from the Fars province, Iran to better understand the
risk of infection with the H9N2 virus in the poultry sec-
tor. The two different diagnostic tests were applied to
assess whether (i) the human exposure to this virus sub-
type can be confirmed and whether (ii) the poultry oper-
ators in the Iranian endemic areas (the Fars province, in
this study) are at risk of exposure to the H9N2 infection.
Results
The HA gene phylogenetic analysis of 88 Iranian H9N2
strains collected between 1998-2014 shows that they be-
long to two different groups of G1 lineage, named sub-
lineage A and sub-lineage B for the purpose of this study
(Fig. 1). Sub-lineage A refers to the H9N2 isolates col-
lected between 1998 and 2007, which apparently are no
longer circulating among the Iranian poultry, while B in-
cludes more recent isolates collected between 2003 and
2014. The amino acid sequence analyses of the Iranian
H9N2 viruses showed that sub-lineage A consists of
47 % (14/30) of the strains with amino acid Q at position
226 (H3 numbering) and 53 % (16/30) with L226 substi-
tution. Interestingly, sub-lineage B encloses mostly
(95 %) (55/58) the strains with amino acid L226. Based
on these results, two Iranian H9N2 isolates representa-
tives of sub-lineages A (A/chicken/Iran/12VIR/9630/
1998) and B (A/chicken/Iran/10VIR/854-5/2008) were















Fig. 1 Neighbour-Joining nucleotide Phylogenetic tree with 1000 bootstrap of the AI H9N2 HA gene of the G1 lineage. Sub-lineages a and b are
highlighted with yellow and blue frames respectively, Iranian Sequences are highlighted in red and two Iranian strains used in serological analyses
are highlighted with gray square. Numbers at the nodes represent bootstrap values (≥70)
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selected as antigens for the serological study (Fig. 1). In
particular, A/chicken/Iran/12VIR/9630/1998 was charac-
terized by the amino acid Q226 while the A/chicken/
Iran/10VIR/854-5/2008 virus had amino acid L at this
position. The HA amino acid sequence distance between
the two selected strains was 8.1 %.
The percentage of seropositive individuals against dif-
ferent influenza viruses obtained with the HI and MN
tests along with the p-value of the chi-square test related
to the association between exposure and response to
each virus tested, per method are reported in Table 1.
Detailed results of serological investigations obtained for
the exposed and unexposed groups against different in-
fluenza viruses are described in the supplementary ma-
terial (Additional file 1: Table S2). Serological results
showed that the prevalence of antibodies against A/
chicken/Iran/12VIR/9630/1998 H9N2 (Q 226) was of
2 % in the exposed group by the HI and MN tests, while
no positive results were identified in the unexposed
group.
An association was observed between professional ex-
posure to poultry species and the presence of antibodies
to the A/chicken/Iran/10VIR/854-5/2008 H9N2 (L 226)
virus, as revealed by the HI and MN test (p < 0.05). The
percentage of positivity was of 12 % for the exposed group
and 2 % for the unexposed group in the HI test, while it
respectively amounted to 17 % and 3 % for the exposed
and unexposed groups in the MN test. Antibody preva-
lence to H1N1pdm 2009 was of 28 % in the exposed ver-
sus 53 % in the unexposed groups by the HI test, and
25 % versus 33 %, respectively, by the MN test. For H3N2,
the prevalence was 36 % in the exposed group compared
to 44 % in the unexposed group with the HI test, while it
was 28 % and 24 % in the exposed and unexposed groups
with the MN test. The titer distribution percentage against
different viruses in different tests (Fig. 2) showed that with
the increase of the titre range from ≥40 to ≥80 and from
≥80 to ≥160, the percentage of antibody positivity drastic-
ally decreased. Cross MN and HI tests on homologues
and different chicken H9N2 hyper immune sera used as
positive controls showed the absence of cross reactivity
with H1N1pdm 2009 and H3N2 seasonal viruses; the
same results were observable in human immune sera for
H1N1pdm 2009 and H3N2, which showed the absence of
a cross reactivity with the two tested H9N2 viruses.
The probability to be positive against A/chicken/Iran/
10VIR/854-5/2008 H9N2, H3N2 and H1N1pdm 2009 vi-
ruses in different tests was calculated. The generalized
linear model for binary responses applied on the H9N2
viruses indicated that the association between profes-
sional exposure or absence of professional exposure and
H9 infection was significant (p = 0.0018). In particular,
the exposed and unexposed groups showed a signifi-
cantly different positivity both in the HI test (9 % vs.
1 %) and in the MN test (13 % vs. 2 %). For the H3N2
virus, the professional exposure was not significantly as-
sociated to the presence of antibodies (p = 0.22). This
means that in both groups the probability of testing
positive is almost similar. Differently, the unexposed
group showed a significantly higher number of individ-
uals (p = 0.001) seropositive to H1N1pdm 2009. If we
consider that the H1N1pdm 2009 subtype does not
circulate in avian species, it can be assumed that the
serological data obtained for this subtype do not depend
on the exposure to poultry species; other factors may
have been at the origin of the distinct immunoreactivity
observed against the H1N1pdm 2009 subtype in the two
groups under study.
Discussion and Conclusion
Results demonstrated that exposure to avian H9N2
viruses had occurred in humans in Iran (Fars province).
In particular, the analysis showed a significantly higher
prevalence of neutralizing antibodies against the A/
chicken/Iran/10VIR/854-5 H9N2 virus in poultry workers
than in the professionally unexposed group. These results
are in accordance with a previously reported study from
Iran by Alizadeh et al. [28] confirming that poultry
workers are at risk of infection from zoonotic avian influ-
enza virus. For the first time in this study, two distinct
H9N2 LPAI viruses were used as antigens for serological
investigations in humans. Interestingly, neutralizing activ-
ity against just one of these two antigens was revealed in
several sera, which has resulted in significant different
Table 1 Positive titer percentages and p-value of the chi square test related to the association between exposure and response to
each virus tested, per method
Triple test average (100 sample subjects)
Virus HI MN
% Positive % Positive p-
value
% Positive % Positive p-
valueExposed group Unexposed group Exposed group Unexposed group
H9N2 A/chicken/Iran/12VIR/9630/1998 2 0 0.01 2 0 0.01
H9N2 A/chicken/Iran/10VIR/854-5/2008 12 2 0.005 17 3 0.001
H1N1pdm 2009 A/California/4/2009 28 53 0.0003 25 33 0.02
H3N2 A/Minnesota/11/2010 36 44 0.02 28 24 0.05
Heidari et al. Virology Journal  (2016) 13:16 Page 4 of 9
prevalence. This is consistent with the amino acid diver-
sity of the two H9N2 antigens used in this study. In fact,
the HA amino acid sequences of A/chicken/Iran/12VIR/
9630/1998 (Q-226) and A/chicken/Iran/10VIR/854-5/
2008 (L-226) differed for 43 amino acids, seven of which
were located in antigenic sites (S158N, S160L, S175D,
E190A, S193N, N208D, Q226L (H3 numbering)) previ-
ously reported by other groups [37–40]. These amino acid
substitutions may account for the different serological re-
activity against these antigens. However, the difference in
prevalence observed in this study between two tested
H9N2 viruses might have different explanations.
The receptor binding properties of A/chicken/Iran/
12VIR/9630/1998 H9N2 (Q-226)-like viruses affect their
ability to infect humans. As a consequence, the infections
of this virus in the exposed population are limited. On the
contrary, the A/chicken/Iran/10VIR/854-5 H9N2 (L-226)
– like viruses, have increased ability to infect humans
resulting in higher prevalence in the exposed population.
However, it should be considered that the molecular ana-
lysis of Iranian H9N2 viruses demonstrated that those har-
bouring the Q-226 mutations apparently are no longer in
circulation. Furthermore, one previous study investigating
the serologic response in humans exposed to avian viruses
concluded that the incidence of seroconversion is low and
that the antibody response after mild/asymptomatic infec-
tions is short-lived [41]. Therefore, the reduction of the
circulation of Q-226 viruses in the poultry in recent times
and/or the low antibody response after infection might be
responsible for the decreased prevalence of antibodies
against these AI viruses.
Consistently with the results discussed so far, the un-
exposed group counting 100 healthy subjects showed a
very low percentage of positivity for H9N2 by the HI
and MN tests, while the distribution of positive titres
against H1N1pdm 2009 and seasonal H3N2 influenzas
were similar in the exposed and in the unexposed
groups.
According to Stephenson et al. [42] the cross reacting
antibodies against H2 might explain the antibody re-
activity against avian H9N2, especially among people
born before 1968. Although we did not test the sera for
this antigen, to evaluate this hypothesis, the age of each
individual who had tested H9 positive was verified. Only
one sample was from a person born before 1968, while
all the others were collected from younger subjects with
an age between 22-46 years, who could not be positive
for H2N2.
The comparison between the serological results ob-
tained using the HI and MN tests against H9N2 showed
that the MN test detected more positive samples within
the same group, however, the triple test results proved
that the HI titer was reasonably more consistent than
the MN test. In addition, different researches have re-
ported that intra-laboratory reproducibility by MN is
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Fig. 2 Graphic distribution of titer categories expressed in percentage among the subjects of the exposed and unexposed groups in the HI and
MN tests
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that may explain the moderate discrepancy observed be-
tween the two serological assays applied for the detec-
tion of antibodies against H1N1pdm 2009 and H3N2
seasonal influenza. Both in the HI and MN tests, the
percentage of positivity for H9N2 decreased with the in-
crease of the titre range; the obtained results were justi-
fied on the grounds that humans have a poor immune
response to infections with avian influenza viruses. For
instance, studies have shown that the individuals with
mild or asymptotic infections had a lower antibody titer
compared to individuals who had seriously developed
the illness [44]. H9N2 AI viruses have some of the spe-
cific molecular markers for the infection of mammals;
however, they are still unable to completely adapt to
mammals and to cause serious disease in humans, which
may explain the low titers observed. As well, the time
elapsed between the infection and sampling dates can
also account for the decrease of the antibody titer.
In conclusion, this study has highlighted the potential
of avian to human transmission of H9N2 AIVs, and indi-
cated that poultry workers are at risk of infection. Avian
transmission of H9N2 viruses in humans can increase
the probability of human adaption, while genetic reas-
sortment with other human seasonal viruses are means
of generating an influenza virus with epidemic or pan-
demic potential. Hence, integrated medical-veterinary
surveillance and research activities are essential in order
to identify the emergence of new influenza viruses, as-
sess the clinical significance of seropositivity and under-
stand more on the mechanisms that favour the virus to
cross the species barrier. In the poultry sector, surveil-
lance and control programmes should be implemented
to reduce the prevalence of H9N2 AIV in poultry popu-
lation and minimize the risk of exposure in poultry
operators.
Methods
Study population and sample collection
The analyses were conducted on the blood sera of 100
workers regularly exposed to poultry (exposed group)
and of 100 individuals with no professional exposure to
poultry (unexposed group). The individuals, belonging
to the exposed group, were recruited among the opera-
tors of the poultry industry and of the University Poultry
Veterinary Hospital, none of whom had been vaccinated
against flu. In particular, blood samples were collected
between September – December 2012 from 70 slaugh-
terhouse workers, 30 poultry house workers and from 10
operators of the University Poultry Veterinary Hospital,
all resident in the Fars province (southern Iran). In Janu-
ary 2013, 100 sera were also collected from subjects
from the same province not professionally exposed to
poultry. 98 % of the individuals included in the study
were males, whose mean age among the poultry workers
was of 32 years (ranging between 18–62). The mean age
in the professionally unexposed group was of 41 years
(range between 18–67). After blood collection the serum
was separated, stored at –20 °C and subsequently sent to
IZSVe for the serological analyses.
Ethics statement
The use of serum samples for research purposes was ap-
proved by the Veterinary University of Shiraz in compli-
ance with the Iranian ethical principles and institutions
and according to the principles expressed in the World
Medical Association Declaration of Helsinki. Informed
consent was obtained from all participating individuals.
Selection of antigens and sera
To select representative H9 antigens to be used in the
serological investigations, the HA gene nucleotide and
amino acid sequences of five Iranian H9N2 AIV isolates
available at IZSVe repository were analysed and com-
pared with the Iranian sequences available in the Gen-
Bank. Subsequently, a nucleotide sequence dataset of 88
Iranian strains along with representative strains of G1
lineage were aligned and phylogenetically analysed con-
structing a Neighbour-Joining phylogenetic tree by the
MEGA 5 (http://www.megasoftware.net) program (see
results). In addition, sera of all individuals were tested
for the presence of antibodies to seasonal A/Minnesota/
11/2010 H3N2 and A/California/4/2009 H1N1pdm 2009
viruses. Positive control sera containing antibodies di-
rected against the selected H9N2 antigens were pro-
duced in SPF chickens. In addition, a panel of different
H9N2, H1N1, H3N2 chicken sera and an H1N1, H3N2
positive human sera were used as controls in the sero-
logical assays.
Serological methods
Hemagglutinin inhibition (HI) test
The HI assay was applied according to the World Health
Organization (WHO) and World Organisation for Animal
Health (OIE) manual [45, 46]. Briefly, 0.5 % (vol/vol)
chicken red blood cell (RBC) solution was prepared by
washing with Phosphate buffered saline (PBS) containing
0.5 % Bovine serum albumin (BSA) (Sigma). To remove
non specific serum inhibitors, the human serum samples
were treated with RDE (receptor destroying enzyme)
(Sigma-Aldrich) that was reconstituted with 5 ml sterile
distilled water. 50 μl of serum was added to 200 μl of RDE
diluted to 100 ml with calcium saline, PH 7.2 and incubated
overnight at 37 °C. Then 5 vol of 1.5 % sodium citrate were
added then heated at 56 °C for 30 min to inactivate
remaining RDE. The treated sera were tested by haem-
agglutination assay to verify the presence of non-specific
agglutination. After that the treated serum (50 μl of each
one) was diluted in two-fold serial dilutions (1:10) with
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25 μl PBS in 96-well V-bottom microtiter plates. Subse-
quently, 25 μl of virus antigens containing 4 HA units were
added to the wells and incubated at room temperature
(RT) for 30–45 min. 50 μl of 0.5 % chicken RBCs were then
added and the plate was incubated further for 45 min at RT
before recording the agglutination titers. The HI test results
were expressed as the reciprocal of the last dilution of the
sample that completely inhibited haemagglutination. In all
the assays control positive serum samples were included,
and all assays were tested in triplicate.
Microneutralization (MN) test
The WHO MN test protocol was applied [47]. The hu-
man serum samples were inactivated by heating at 56 °C
for 30 min H9N2, H3N2 and H1N1pdm virus stocks
used in our analyses were titrated in the presence of
TPCK-trypsin (2 μg/ml) (Sigma-Aldrich) for determin-
ation of tissue culture infectious dose (TCID50). 10 μl of
treated sera were added to 96 well cell culture plates
(Costar) and 2-fold serial dilutions were performed. In-
oculum was prepared in virus diluent with the addition
of TPCK-trypsin (2 μg/ml) so that 50 μl contained 100
TCID50 of the respective virus. Fifty microliters of virus
inoculum was added to the wells, the virus serum mix-
ture was subsequently incubated for 1 hr at 37 °C, 5 %
CO2. A back-titration of the virus inoculum was per-
formed in each assay using 2 fold serial dilutions. 100 μl
MDCK cells (1.5 × 104 cells /well) were then added to
each well and the plate was incubated overnight at 37 °C,
5 % CO2 (18–20 hrs). The plate was then fixed with
100 μl/well of cold fixative (80 % Acetone in PBS) for
10 min. The virus was detected with an anti-Influenza A,
Nucleoprotein monoclonal antibody (Merck Millipore)
and Peroxidase conjugated-goat anti-mouse IgG (γ) (KPL)
as secondary antibody using ELISA. All serum samples
and controls were tested in triplicate.
Criteria for seropositivity
The WHO guidelines for vaccine evaluation suggest that a
neutralizing antibody titre ≥40 indicate higher than 50 %
protection against influenza A virus infection or disease.
Based on this consideration, an individual with an antibody
titer ≥40 was considered positive for different serotype in
MN and HI tests [41].
Statistical Analyses
The Geometric Mean titers (GMTs) of the triple test
per method (HI and MN) was calculated for each sub-
ject checked for the virus of interest. A binary variable
was created to identify the positive/negative sample. An
average titre lower than 40 identified negative samples,
whereas an average titre higher than 40 identified posi-
tive samples. The Chi square test was used to verify the
possible association between positivity and exposure,
for each method and virus. The GLM (Generalized lin-
ear model) for binary responses was used to estimate
the probability to have a positive reaction for each
tested virus, considering simultaneously the methods
(HI and MN), the groups (exposed and unexposed) and
their interaction as variables. The Maximum Likelihood
method was used to estimate the parameters of the
model. The Type III F-tests were applied to evaluate the
overall effect of specified variables in the model. P-values
lower than 0.10 were considered as significant [48]. SAS
9.3 software was used to fit the statistical analysis.
Additional file
Additional file 1: Table S2. Results of serological investigations obtained
for the different categories of exposed and unexposed groups against
different influenza viruses. (DOC 110 kb)
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